Boston Scientific stock faces negative outlook as growth slows

Boston Scientific faces a tougher credit backdrop after S&P Global Ratings revised its outlook to negative from stable on November 6, 2026. The agency affirmed the medical-device maker's A- issuer and senior unsecured debt ratings, while leaving its A-2 short-term rating unchanged. The action highlights slower growth in two former expansion engines and the balance-sheet burden of the planned Penumbra acquisition.

Boston Scientific stock traded at 40.84 euros on Lang & Schwarz at 12:44 CET on Thursday, November 12, 2026. The quote is a current market indication; the available Xetra page did not provide a dated closing price for a daily comparison.

Rating outlook turns negative

In its November 6 rating action, S&P Global Ratings said WATCHMAN and electrophysiology were facing market and competitive headwinds. It expects the weakness to continue into 2027 while Boston Scientific works to stabilize market share and restore growth.

The agency projects revenue growth of 4.4 percent in 2026 and 9 percent in 2027. That compares with growth in the mid- to high-teens in 2024 and 2025. S&P said WATCHMAN represents 10 percent of revenue and electrophysiology 16 percent, making the two franchises material to the group's growth profile.

Penumbra raises leverage demands

The planned 14.5 billion US dollar acquisition of Penumbra is expected to close in early 2027, subject to regulatory clearances. S&P expects adjusted leverage to rise above 3.6 times after completion, well above its 2.5-times downside trigger, and to remain elevated for the following two years.

Boston Scientific is seeking 500 million US dollars in restructuring savings through 2029. The rating agency nevertheless expects the company to invest in commercial support for its key franchises while integrating Penumbra. It sees a path back to leverage of 2.5 times by year-end 2028, but that projection depends on a recovery in WATCHMAN and electrophysiology, mid-single-digit growth in other core franchises and restrained capital allocation.

Execution becomes the key test

The credit assessment leaves the company with several operational priorities. Boston Scientific must address slower left atrial appendage closure activity, defend its electrophysiology position against larger competitors and integrate Penumbra without extending the deleveraging period. S&P said a further downgrade could become likely if leverage remains above 2.5 times for longer than expected, or if the company pursues significant additional acquisitions or share repurchases.

The broader portfolio provides a counterweight. S&P said cardiovascular and MedSurg businesses outside WATCHMAN and electrophysiology account for 74 percent of the portfolio and are expected to grow at mid-single-digit rates. Penumbra would also add a complementary neurovascular and cardiovascular business with 2025 revenue of roughly 1.4 billion US dollars and mid- to high-teens growth.

Developments across the S&P 500 remain relevant for the valuation backdrop of large US medical-device companies, but the immediate investor focus is on Boston Scientific's franchise recovery and balance-sheet execution.

Further developments will center on regulatory progress for Penumbra, the performance of WATCHMAN and electrophysiology, and the company's ability to reduce leverage. More news and analyses on Boston Scientific stock.